Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mezagitamab in Primary IgA Nephropathy
NCT06963827Phase 3Recruiting
- Sponsor
- Takeda
- Start
- Jul 2025
- Primary completion
- Sep 2028
- Modality
- Monoclonal Antibodies
- Countries
- 26
01
Overview
A Phase 3 trial of mezagitamab in immunoglobulin A nephropathy (IgAN), sponsored by Takeda. Started Jul 2025; status: recruiting.
02
Drugs
mezagitamab
03
Conditions
immunoglobulin A nephropathy (IgAN)
Beyond the preview
Go deeper on NCT06963827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06963827.